Kestra Advisory Services’s Crinetics Pharmaceuticals CRNX Stock Holding History

Kestra Advisory Services’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,922	Closed	-$136K	–	3374
2025 Q4	$136K	Buy	+2,922	New	+$130K	﹤0.01%	3201
2025 Q1	–	Sell	-5,177	Closed	-$265K	–	2785
2024 Q4	$265K	Buy	5,177 +70	+1%	+$3.92K	﹤0.01%	2323
2024 Q3	$261K	Buy	5,107 +24	+0.5%	+$1.24K	﹤0.01%	2186
2024 Q2	$228K	Buy	+5,083	New	+$235K	﹤0.01%	2313
2024 Q1	–	Sell	-7,400	Closed	-$263K	–	2471
2023 Q4	$263K	Sell	7,400 -31	-0.4%	-$951	﹤0.01%	1931
2023 Q3	$221K	Buy	+7,431	New	+$153K	﹤0.01%	1879

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Kestra Advisory Services's CRNX Position: Q1 2026 in Review

Kestra Advisory Services sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 2,922 shares — an estimated $136K sold.

Kestra Advisory Services first reported a position in CRNX in Q3 2023 and held it in 6 quarters. The position peaked at $265K in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

Kestra Advisory Services reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Kestra Advisory Services sold 2,922 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $136K.
Kestra Advisory Services first reported a position in Crinetics Pharmaceuticals in Q3 2023 and held it in 6 quarters.
Kestra Advisory Services's Crinetics Pharmaceuticals position peaked at $265K in Q4 2024.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.